Structure Therapeutics (GPCR) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Pipeline overview and strategy

• Focus on oral small molecule medicines for metabolic diseases, targeting GPCRs such as GLP-1, amylin, GIP, glucagon, apelin, and LPA1 receptors.

• Lead asset GSBR-1290 is an oral GLP-1 agonist, with a broad pipeline including oral amylin and apelin receptor agonists.

• GSBR-1290 has shown 6.2-6.9% body weight loss over 12 weeks in phase IIa, with plans to move into a 36-week phase IIb study.

• Oral amylin candidate expected to enter the clinic by end of next year; apelin receptor agonist is phase II-ready.

• LPA1 program for idiopathic pulmonary fibrosis is in phase I, with data expected in the first half of 2025.

Clinical data and differentiation

• GSBR-1290 demonstrated a clean safety profile with no liver toxicity or off-target effects in over 200 subjects.

• Replacement cohort in phase IIa showed nearly 9% weight loss, attributed to improved clinical oversight.

• Tolerability, especially GI side effects, is expected to improve with slower titration in upcoming studies.

• Tablet formulation showed similar efficacy and tolerability to capsule, with clear attenuation of GI symptoms over time.

• Plans to test doses higher than 120 mg in future studies, leveraging a strong safety margin.

Manufacturing and scalability

• Manufacturing capacity enables production of 6,000 metric tons, sufficient for over 120 million patients.

• Oral small molecules offer significant scalability advantages over oral peptides.